Aktieanalyser | Från 10+ populära analyshus

• Idag 10:57

Lipum Q4 report: Focus on clinical progress - Redeye

Lipum

• Idag 09:01

Flexion Mobile: Too Big to Ignore - Redeye

Redeye updates its view on Flexion Mobile following its strong Q4 2022 report released on March 22.

Flexion Mobile

Analys | Evli

• Idag 08:04

Administer: Growth in place, profitability up next - Evli

Administer reports its H2/2022 results on March 30th.

Administer

• Igår 09:53

Q-linea: A targeted ASTar launch strategy - Redeye

Q-linea is in the early stage of its targeted European launch strategy...

Q-Linea

• Igår 08:49

Smart Eye: Study presented predicting worldwide DMS adoption – should support positive cash flow in H2 2024 - Redeye

Redeye thinks the presented study of global and European DMS adoption supports Smart Eye becoming ca...

Smart Eye

Analys | Mangold

• Igår 08:03

Alzinova: Ny Alzheimerkandidat stormar fram - Mangold

För Alzinova stundar en spännande period då ny interimdata från Alzheimer-projektet ALZ-101 ska läsa...

Alzinova

Analys | Nordea

• Igår 07:57

Rovio: Concludes takeover discussions with Playtika, but continues the strategy review - Nordea

Rovio

• I förrgår 16:05

Faron Pharmaceuticals: Positive FDA Feedback on Bexmarilimab - Redeye

Redeye is encouraged to learn that Faron has received positive FDA feedback and recommendations for ...

Faron Pharmaceuticals

Analys | Analysguiden

• I förrgår 15:12

QuiaPEG Pharmaceuticals: Intensifierat arbete inom affärsutveckling - Analysguiden

Ökat fokus på affärsutveckling under 2022 och flera pågående diskussio...

QuiaPEG Pharmaceuticals

Analys | Edison

• I förrgår 14:33

CoinShares International: En troligen fördelaktig överlevare av “kryptovintern” - Edison

CoinShares International (CS) rapporterade en måttlig EBITDA-förlust p...

CoinShares

• I förrgår 14:01

Eevia Health: Getting Closer to Black Numbers after Operating Improvements - Analyst Group

Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) is at a stage where the Company i...

Eevia Health

• I förrgår 09:37

Alligator Bioscience: Rights Issue Announced– We Pause Our Coverage - Redeye

Redeye gives a short comment on the announced rights issue and pauses its coverage.

Alligator Bioscience

• I förrgår 09:05

Ovzon: Inconvenient, but not a catastrophe - ABG

Ovzon

• I förrgår 08:25

Flexion Mobile Q4 2022: Strong growth in a challenging market - Redeye

Redeye comments on Flexion Mobiles Q4 2022 report. Strong revenue growth of 108% y/y, despite a chal...

Flexion Mobile

• I förrgår 07:38

Zwipe: Decent subscription rate - Redeye

Redeye comments on the outcome of Zwipe’s rights issue, which was subs...

Zwipe

• I förrgår 07:37

Alcadon: Raises capital to meet high demand - ABG

Completes a SEK 52.6m directed share issue 4.5% EPS dilution, 4.

Alcadon Group

• 21 Mar 11:24

AcuCort: Tar kliv i Norden mot kommersialisering i närtid - Analyst Group

AcuCort AB (”AcuCort” eller ”Bolaget”) har erhållit godkännande inom samtliga nordiska länder för Bo...

AcuCort

• 21 Mar 11:16

Analyst Group Comments on OrderYOYO's Annual Report 2022

OrderYOYO published, March 20, the company’s annual report of 2022, and are showing progress.

Analys | Penser

• 21 Mar 11:02

Talkpool: In i 2023 med fokus på marginaler och kassaflöden - Penser

Talkpool

• 21 Mar 10:37

Wyld Networks: Plan to expand into NB-IoT/5G - Redeye

Redeye responds to Wyld’s press release from today, revealing the company’s intention to upgrade its...

Wyld Networks

• 21 Mar 09:34

Careium: Set for positive FCF in Q1 - ABG

5% Q1e adj. EBITA margin and 7% org. growth Limited adj.

Careium

Analys | Analysguiden

• 21 Mar 09:33

AlzeCure Pharma: Siktar på utlicensiering eller samarbete 2023 - Analysguiden

AlzeCure möts av ett ökat intresse från större läkemedelsbolag och mål...

AlzeCure Pharma

Analys | Nordea

• 21 Mar 09:08

Investors House: CMD highlights transformation to more stable operations and no hurry into new investments or M&A - Nordea

Investors House hosted a webcast CMD on 20 March. The company gave an update on current operations o...

Investors House

• 21 Mar 07:35

Nepa: Negative share-price development likely to turn when cost savings are realized throughout 2023 - Redeye

Redeye states that Q4 came in on the weak side and that the outlook for Q1 was weak, but far from ca...

Nepa

• 21 Mar 07:35

Clavister: Defense customer expects a surge in orders - ABG

Clavister

• 20 Mar 13:56

Brain+ expands its first sales contract, close to doubling it - Analyst Group

On March 20, 2023, Brain+ A/S (“Brain+” or “the Company”) announced that the Danish municipality Her...

Brain+

• 20 Mar 13:56

WGS Wellness Group A/S blir EcoRubs distributör i Danmark - Analyst Group

EcoRub tillkännagav den 2 mars att bolaget lanserar en ny produktserie...

EcoRub

• 20 Mar 13:08

Gomspace: Rights issue moving ahead - ABG

Raising SEK 122m at a SEK 1.3 subscription price The board of director...

GomSpace

• 20 Mar 13:06

Energy Save: Accelerates the business plan - Redeye

Redeye updates its view on Energy Save after the Q3 2022/2023 report.

Energy Save